A Smart + Strong Site
Subscribe to:
POZ magazine

Back to home » Treatment News » Top Stories

February 29, 2008
GSK Comments on ACTG 5202 Study Changes
GlaxoSmithKline (GSK), the maker of Epzicom (abacavir plus lamivudine), has issued a statement responding to changes the AIDS Clinical Trials Group (ACTG) made last week to study A5202.
HIV Treatment Increases Survival, Not Heart Attack Risk
Antiretroviral treatment does not increase a person’s risk for developing heart disease or heart attacks, but does significantly increase survival, say the authors of a large study published in the March 1 issue of the Journal of Acquired Immune Deficiency Syndromes.
February 28, 2008
Epzicom Efficacy Concerns Lead to ACTG Study Changes
A data and safety monitoring board (DSMB) for the AIDS Clinical Trial Group (ACTG) has recommended changes to a large clinical trial comparing Epzicom (abacavir plus lamivudine) to Truvada (tenofovir plus emtricitabine) in combination with either Sustiva (efavirenz) or Norvir (ritonavir)-boosted Reyataz (atazanavir).
February 27, 2008
Safe for Some to Switch to Viramune With Higher CD4 Counts
People who achieve undetectable viral loads and high CD4 counts while using antiretroviral therapy may safely switch to a regimen that contains Viramune (nevirapine), say the authors of a study published in the March 15 issue of Clinical Infectious Diseases.
February 26, 2008
New Prezista 600 mg Tablet Approved
The Food and Drug Administration (FDA) has approved a 600 mg tablet version of the protease inhibitor Prezista (darunavir), sold by Tibotec, thus reducing the number of pills a person must take each day.
GeoVax Vaccine to Move Forward
The HIV Vaccine Trials Network (HVTN), part of the National Institutes of Health (NIH), has decided to proceed with a phase IIa safety study of an HIV vaccine produced by the company GeoVax.
February 25, 2008
Growth Hormone Boosts Thymus T-Cell Production
Recombinant human growth hormone (rhGH), manufactured as Serostim by Serono Laboratories and approved for the treatment of AIDS-related wasting syndrome, may also prove to be useful as an immune-based therapy in people living with HIV.
February 22, 2008
Discordant Responders Have Faster Disease Progression
HIV-positive people who have discordant responses to antiretroviral therapy—for example, an undetectable viral load but a blunted CD4 immune response—may progress faster to AIDS or death than those who respond both virologically and immunologically to treatment, according to a new study to be published in an upcoming issue of the Journal of Acquired Immune Deficiency Syndromes.
February 21, 2008
Drug Use Linked to Infection With Resistant Virus
Gay and bisexual men who used ecstasy, GHB and/or crystal were more likely to be infected with HIV that is resistant to antiretroviral drugs, say the authors of a study to be published in a forthcoming issue of the Journal of Acquired Immune Deficiency Syndromes.
February 20, 2008
Dipstick Kidney Test Less Accurate in HIV
A urine dipstick test used to detect abnormal levels of protein in people with HIV and kidney disease was found to be largely inaccurate, according to new data from a study published in the February 1 issue of the Journal of Acquired Immune Deficiency (JAIDS) and reported by AIDSmap.
Study Links Zerit and Retrovir With Diabetes Risk
People taking the nucleoside reverse transcriptase inhibitors (NRTIs) Zerit (stavudine), Retrovir (zidovudine) and Videx (didanosine) were found to have a higher risk of developing diabetes mellitus, say the authors of a large international study published in the February 11 issue of Diabetes Care.
February 19, 2008
Starting Treatment With Higher CD4s Cuts Death Rate
People who start antiretroviral treatment with CD4 counts above 350 have the lowest risk of disease progression and death compared with people who start at CD4 counts below 350, say the authors of a study published in the February 1 issue of the Journal of Acquired Immune Deficiency Syndromes (JAIDS) and reported by AIDSmap.
February 15, 2008
HIV Treatment Improves, but Doesn’t Restore, B Cells
Most types of B cells return to normal levels within 12 months after starting antiretroviral therapy, leading to a partial—but incomplete—recovery of the immune system, say researchers of a new study published in the Journal of Infectious Diseases.
February 14, 2008
Suppressing HIV Improves Kidney Function
Reducing viral load using antiretroviral therapy can greatly improve renal function in people with HIV and kidney disease, according to a new study published in the February 19 issue of AIDS.
February 13, 2008
Acyclovir Doesn’t Reduce HIV Infection Risk in HSV-2-Positive People
The anti-herpes drug acyclovir did not reduce the risk of acquiring sexually transmitted HIV when given to men and women infected with herpes simplex virus-2 (HSV-2), according to the authors of a study reported last week at the 15th CROI in Boston.
February 12, 2008
Extended-Release Viramune Begins Study
Boehringer Ingelheim, the maker of Viramune (nevirapine), announced that it has begun enrolling participants in a clinical trial of an extended-release formulation of the drug for once-daily dosing.
VIRxSYS Gene Therapy Makes Progress
Researchers have reported encouraging results from a clinical trial of a gene therapy approach to treat HIV.
Women & HIV Treatment
Regan Hofmann talks with Judith Currier, MD, about treatment and research advances in women living with HIV, and learns that many women are doing quite well.
World of Prevention: Vaccines and More
Regan Hofmann talks with Susan Buchbinder, MD, of the San Francisco Department of Public Health about new data on circumcision, vaccines, microbicides and other possible HIV prevention tools.
Condom-Free Sex? Controversial Swiss Declaration
Regan Hofmann talks with Bernard Hirschel, MD, of the University Hospital, Geneva, Switzerland about a controversial Swiss position paper declaring that HIV-positive people with undetectable viral loads cannot transmit HIV.
February 11, 2008
New Hope for Treatment Experienced
David Evans talks with UCLA researcher, David Hardy, MD, about the latest data on antiretroviral options for people who are heavily treatment experienced and learns that the treatment landscape has changed radically.
February 09, 2008
Prezista Effective and Safe in Positive Kids
Prezista is showing promise for treatment-experienced HIV-positive children between the ages of six and 17, according to early data from a clinical trial reported this week at the 15th CROI in Boston.
Durable Efficacy and Safety With Isentress Treatment
Year-long follow-up data from two Phase III clinical trials of Isentress were reported this week at the 15th CROI, confirming that the drug offers durable antiretroviral activity to those in need of new treatment options.
Good Bacteria Reduces Vaginal HIV Levels
Healthy bacteria (Lactobacillus) limits the amount of HIV detected in the genital secretions of women infected with the virus, Seattle and Rochester researchers report.
February 08, 2008
HIV & Your Heart: Part I
David Evans talks with St. Luke’s Roosevelt’s Donald Kotler, MD about the role of inflammation in heart disease and surprising research on Ziagen and heart attacks.
HIV & Your Heart: Part II
David Evans continues his discussion with Donald Kotler, MD, talking about diet, lifestyle and new treatments to combat belly fat.
Morris Jackson: Survivor and Treatment Activist
David Evans talks with long-term survivor and treatment activist, Morris Jackson, about conference highlights and the benefits of getting involved.
February 07, 2008
Prevention and Women: HIV-positive and HIV-negative
Regan Hofmann talks with Harvard’s Valerie Stone, MD, about the challenges and opportunities in working with women, both HIV-positive and HIV-negative, to prevent HIV transmission.
Once-Daily Viramune Is at Least as Efficient as Twice-Daily Dosing
Once-daily Viramune is at least as effective as twice-daily dosing of the non-nucleoside reverse transcriptase inhibitor (NNRTI), according to a review of data from two European cohort studies.
Durable Efficacy Seen in Studies of New NNRTI Intelence
Forty-eight weeks of treatment with Intelence, combined with an optimized background regimen, is associated with greater viral load reductions and CD4 count increases compared to placebo among HIV-positive patients with limited treatment options due to drug resistance.
Nanotechnology May Yield Long-Lasting Meds
Some of the most exciting news to emerge from the 15th CROI this week in Boston involved the fruitful discoveries stemming from the fusion of two modern sciences: drug discovery and nanotechnology.
February 06, 2008
Male Circumcision Doesn't Reduce Women's HIV Risk
Male circumcision may reduce men’s risk of being infected with HIV, but it doesn’t appear to curb the transmission of the virus from men who are already positive to their female partners, according to new data reported earlier this week at the 15th Conference on Retroviruses and Opportunistic Infections in Boston.
TDM-Guided PI Dose Increases of Limited Benefit
Using therapeutic drug monitoring to guide protease inhibitor dosing in treatment-experienced patients was generally considered to be ineffective, but with benefits seen in black and Hispanic patients, according to the results of a recently completed ACTG study. 
Refining HIV Treatment for New Med Takers
David Evans talks with Los Angeles HIV specialist, David Hardy, MD, about research to refine and enhance treatment for people taking HIV medications for the first time.
February 05, 2008
AIDS Survival: Progress Not Perfection
David Evans talks with Douglas Ward, MD, about success in controlling AIDS-related complications and progress still to be made.
Once- vs. Twice-Daily Kaletra Tablets: Similar Safety and Potency
Once- and twice-daily doses of Kaletra tablets have similar tolerability and comparable efficacy, according to 48-week results from a clinical trial reported yesterday at the 15th Conference on Retroviruses and Opportunistic Infections (CROI). 
Epzicom Comparable to Truvada as First-Line NRTI Choice
Epzicom is comparable to Truvada in people starting HIV treatment, according to data from the first head-to-head comparison of the two leading NRTI options.
February 04, 2008
Vicriviroc Shows Well in Treatment-Experienced Patients
Forty-eight weeks of therapy with the CCR5-blocking entry inhibitor vicriviroc, notably a 30 mg once-daily dose of the drug combined with a Norvir (ritonavir) booster, leads to greater viral load reductions compared with placebo among HIV-positive patients with limited treatment options due to drug resistance.
Abacavir, Didanosine Linked to Increased Heart Attack Risk
Abacavir—the active drug in Ziagen and a component of Epzicom and Trizivir—may double the risk of a heart attack in HIV-positive people currently using the drug, a potential concern for individuals with other major heart disease risk factors.
Norvir/Reyataz Comparable to Kaletra for First-Line Therapy
Early data from a study comparing Norvir-boosted Reyataz to Kaletra suggest that both drugs have similar effectiveness in HIV-positive patients starting therapy for the first time.
Sexual Reinfection With HCV Following Treatment
Reinfection with the hepatitis C virus (HCV), after undergoing successful treatment for the liver infection, can occur following a subsequent sexual exposure to the virus, according new data involving eight gay and bisexual HIV-positive men reported today at the 15th CROI. 
February 01, 2008
Parasitic Drug Shows HIV-Fighting Promise
A drug used to treat parasitic infections in developing countries may play a valuable role fighting HIV alongside standard antiretrovirals, according to new research published January 31 in the online scientific journal Retrovirology.
Gilead Loses Key Patents on Tenofovir
The United States Patent Office has rejected four key patents to Gilead Sciences for its antiretroviral drug tenofovir DF (found in Viread, Truvada and Atripla), according to widespread news reports.
Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
FDA Approves New Single-Tablet HIV Regimen, Triumeq
Life Expectancy for Young People With HIV Is Nearly Normal
A 15-Year Jump in Life Expectancy for People With HIV
Scientists Devise Method of Snipping HIV From Immune Cells
Monkey HIV Vaccine Success Opens Door for Human Trials
HIV Combo Pill Less Toxic Thanks to New Form of Tenofovir
Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?

February 2016
January 2016
December 2015
November 2015
October 2015
September 2015
August 2015
July 2015
June 2015
May 2015
April 2015
March 2015
February 2015
January 2015
December 2014
November 2014
October 2014
September 2014
August 2014
July 2014
June 2014
May 2014
April 2014
March 2014
February 2014
January 2014
December 2013
November 2013
October 2013
September 2013
August 2013
July 2013
June 2013
May 2013
April 2013
March 2013
February 2013
January 2013
December 2012
November 2012
October 2012
September 2012
August 2012
July 2012
June 2012
May 2012
April 2012
March 2012
February 2012
January 2012
December 2011
November 2011
October 2011
September 2011
August 2011
July 2011
June 2011
May 2011
April 2011
March 2011
February 2011
January 2011
December 2010
November 2010
October 2010
September 2010
August 2010
July 2010
June 2010
May 2010
April 2010
March 2010
February 2010
January 2010
December 2009
November 2009
October 2009
September 2009
August 2009
July 2009
June 2009
May 2009
April 2009
March 2009
February 2009
January 2009
December 2008
November 2008
October 2008
September 2008
August 2008
July 2008
June 2008
May 2008
April 2008
March 2008
February 2008
January 2008
December 2007
November 2007
October 2007
September 2007
August 2007
July 2007
June 2007
May 2007
April 2007
March 2007
February 2007
January 2007
December 2006
November 2006
October 2006
September 2006
August 2006
July 2006
June 2006
May 2006
April 2006
February 2006
October 2005

Quick Links
About HIV and AIDS
The Cure
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Conference Coverage
Health Services Directory
POZ Magazine
AIDSmeds on Twitter

Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014

21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014

7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013

more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.